Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Traditional and personalised models of therapy in gastrointestinal and endocrine tumours: the role of histological and clinical markers

Share :

17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC 2013)

27 Sep 2013
Sorry, this item is currently unavailable.
Published: 8 Nov 2013
Views: 3549
Rating:
Save
Dr Jaume Capdevila - Vall d'Hebron University Hospita, Barcelona, Spain

Speaking at the AstraZeneca sponsored satellite symposium 'The revolution in peronalised healthcare: Towards improved outcomes in oncology', at the 2013 European Cancer Congress, Dr Capdevila discusses the role of histological and clinical markers in the modern field of personalised care for GI and endocrine tumours.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment
Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...
Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )
7 Nov 2023
Potential benefit to response rates from trastuzumab added to perioperative...
Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru
Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )
9 May 2023
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...
Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )
6 Apr 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
ASCO GU 2023: CRPC updates
Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou
ASCO GU 2023: CRPC updates ( Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou )
19 Feb 2023
Latest in PARP inhibitors and combination therapies for prostate cancer
Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...
Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )
19 Feb 2023
Loco-regional management after neoadjuvant chemotherapy
Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA
Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )
1 Feb 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation